Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for untreatable liver cancer

NCT ID NCT07204327

Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo or radiation works for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and Asia will be included. The goal is to see if this approach helps people live longer and controls the cancer better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with unresectable hepatocellular carcinoma (uHCC) treated in routine clinical practice across multiple centers in China and the Asia-Pacific region, receiving atezolizumab plus bevacizumab in combination with locoregional therapies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years at initiation of atezolizumab plus bevacizumab (Atezo+Bev) * Histologically or radiologically confirmed unresectable hepatocellular carcinoma (uHCC) according to national guidelines * Initiated first-line Atezo+Bev treatment between October 28, 2020 and July 31, 2025 * Received ≥1 locoregional therapy (TACE, HAIC, TARE, ablation, or radiotherapy) within ±2 months of Atezo+Bev initiation * At least one follow-up record available after treatment initiation Exclusion Criteria: * Prior systemic therapy for HCC before Atezo+Bev initiation * Concurrent participation in interventional clinical trials at baseline * Diagnosis of other malignancies at baseline (except basal cell carcinoma of the skin)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unresectable hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unresectable hepatocellular carcinoma

Contacts and locations

Locations

  • Zhongda Hospital, Southeast University

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.